Primary Hepatocytes Market

Primary Hepatocytes Market Outlook (2024 to 2034)

The global primary hepatocytes market recorded a valuation of around US$ 189.5 million in 2019. The demand for primary hepatocytes of superior quality is growing constantly due to ongoing breakthroughs in liver cell research in publicly funded as well as privately owned biotech firms. Based on the analysis of such trends, Fact.MR estimates that the primary hepatocytes market is anticipated to be around US$ 255.6 million in 2024.

As liver toxicity researchers are investigating new applications and treatment strategies, the need for dependable supplies of fresh hepatocytes for in vitro liver models is anticipated to rise further in the coming days. So, the driving demand for detoxification and protein synthesis is leading to significant growth for primary liver cells or hepatocytes at a rate of 6.6% per year through 2034. In terms of value, the primary hepatocytes industry is forecast to reach a valuation of US$ 486 million by 2034 end.

Primary Hepatocytes Market Trends and Analysis

The demand for primary hepatocytes has increased manifold in the last few years with the rise in funding for liver disease research, which includes cirrhosis and non-alcoholic fatty liver disease (NAFLD). Likewise, the demand for hepatocytes to investigate non-alcoholic steatohepatitis (NASH) and other complications is rising with the growing focus on common liver illness.

Primary hepatocytes are increasing with the rise of 3D hepatocyte culture models being used to replicate in vivo settings more accurately. So, market players are now focused more on providing hepatocytes appropriate for 3D culture applications and enabling end users to do more physiologically realistic research.

Report Attributes	Details
Estimated Market Value (2024E)	US$ 255.6 million
Forecasted Market Value (2034F)	US$ 486.6 million
Global Market Growth Rate (2024 to 2034)	6.6% CAGR
3D (Spheroid) Hepatocytes Segment Growth Rate (2024 to 2034)	8.1% CAGR
Horse Segment Growth Rate (2024 to 2034)	10.3% CAGR
Phospholipoids Assays Segment Growth Rate (2024 to 2034)	7.7% CAGR
Contract Research Organizations Segment Growth Rate (2024 to 2034)	7.5% CAGR
North America Market Share (2024)	34.6%
East Asia Market Share (2024)	18.5%
Key Companies Profiled	Thermo Fisher Scientific Corning Inc. Lonza Axol Bioscience Ltd. LifeNet Health SEKISUI XenoTech, LLC Cytes Biotechnologies Cell Biologics, Inc. ZenBio, Inc. BioIVT. ScienCell Research Laboratories, Inc. Kerafast Takara Bio Inc. Kosheeka

What are Emerging Trends that are Driving the Primary Hepatocytes Market Growth?

“Rise in In Vitro Liver Toxicology Testing and Regulatory Emphasis on Drug Safety Assessment”

Hepatocytes that precisely represent individual patient differences are becoming more and more necessary as the contemporary healthcare sector is continuously shifting toward individualized care. In line with this development, industry players are concentrating on offering primary hepatocytes with a range of genetic origins to aid in individualized drug response and liver toxicity studies.

The viability and usability of cryopreserved hepatocytes have improved with new developments in hepatocyte storage methods. Therefore, suppliers are observed to be investing more in enhancing cryopreservation techniques to give their clients high-quality hepatocytes.

Country-wise Insights

Country	Regional Market CAGR (2024 to 2034)
United States	5.1% CAGR
South Korea	8.5% CAGR

Who is the Leading Supplier of Primary Hepatocytes Cells for the East Asia Market?

“Integration of Modern Technologies in Hepatocyte Differentiation and Isolation is Driving the Market in China”

Industry players in East Asia meet the unique needs of the huge pharmaceutical industry base by offering hepatic cells that are critical to comprehending the course of several liver illnesses and developing treatment strategies. Through the forecast years, the adoption of primary hepatocytes in China, Japan, and South Korea is poised to soar with a 7.3% CAGR and reach a combined market valuation of US$ 96 million by its end.

China is the leading producer and consumer of primary hepatocytes as well as hepatocyte isolation kits in East Asia, and it holds nearly half of the regional market share. The industry players in China have increased their efficiency and cell yield in recent years by incorporating innovative techniques into hepatocyte isolation procedures. Modern methods used by Chinese suppliers to expedite hepatocyte differentiation and guarantee a steady supply of hepatic cells for researchers are poised to drive the regional market further.

In 2024, the net worth of the primary hepatocytes industry is estimated to be around US$ 23 million, and over the next ten years, it is likely to expand at a 6.5% rate. Meanwhile, the demand for primary hepatocytes in Japan and South Korea is poised to grow at a higher rate due to the strengthening of pharmaceutical research industries. While the Japanese market is likely to follow a 7.8% CAGR, the market in South Korea is expected to follow a robust 8.5% CAGR between 2024 and 2034.

Why is the United States Dominating the Global Primary Hepatocytes Market?

“Emphasis on 3D Models of Hepatocyte Culture is Driving the Advancement of the United States Market”

The net worth of the primary hepatocyte industry in the North is figured to be around US$ 88 million in 2024. The proliferation of biobanking programs, guaranteeing the availability of different hepatocyte samples for a range of research uses, is driving the market in North America. As per Fact.MR estimates, the demand for primary hepatocytes is likely to grow at a rate of 5.4% per year, giving rise to an industry size of US$ 150 million by 2034 end.

The United States primary hepatocytes market plays a pivotal role in the development and advancement of the market in North America by contributing nearly 80% of the total revenue in the region. So, present-day hepatocyte suppliers guarantee adherence to regulatory requirements by following ethical concerns and regulatory adjustments in different countries.

The market of primary hepatocytes in the United States is going to surge with an estimated CAGR of 5.1%, creating a market worth around US$ 119 million by 2034. On the contrary, the regional industries in Canada and Mexico, with a valuation of US$ 14 million and US$ 2 million in 2024, respectively, are developing at a faster rate.

Category-wise Insights

Who are the Prominent End User for Primary Hepatocytes Market Participants?

“Academic and Research Institutes are Ramping up Hepatocyte-based Screening Activities”

Based on several industries that constitute different end-user verticals for the market under study, biopharmaceutical companies create more than half of the total demand. The sourcing of primary hepatocytes has traditionally remained essential for biopharmaceutical companies because they require human liver cell lines for early-stage drug testing. As per the market predictions, this segment is likely to expand with a CAGR of 6.1% and contribute US$ 235.8 million by 2034 end.

In recent years, there has been a rising demand for human liver cell lines in academic and research institutes. Primary hepatocyte applications are increasing via collaborations of primary hepatocyte providers with academic and research institutions. Besides supplying necessary resources and hepatocyte isolation kits, market players are also actively interacting with researchers to learn about the evolving needs and scale up their business.

Which Species are Predominantly Used by Primary Hepatocytes Industry Suppliers?

“Greater Resemblance of Horse Liver Cell Line Makes it a Preferred Choice for Research Studies”

Among the different species utilized for the extraction of liver cell lines, the human segment is expected to contribute to 62.4% of the total demand in 2024. As primary hepatocyte applications are required for precise predictions of drug metabolism and liver toxicity, there is a growing demand for hepatocytes that closely resemble human hepatocyte cell lines.

Recently, private entities that supply liver cell lines obtained from a variety of species to comprehend liver disease processes and advance research are gaining prominence in the healthcare sector. Notably, the segment for hepatocyte isolation from horse species is expected to witness a lucrative growth rate of 10.3% through the projected years.

Competitive Landscape

Key players in the primary hepatocytes market include Thermo Fisher Scientific, Corning Inc., Lonza, Axol Bioscience Ltd., LifeNet Health, SEKISUI XenoTech, LLC, Cytes Biotechnologies, Cell Biologics, Inc., ZenBio, Inc., BioIVT, ScienCell Research Laboratories, Inc., Kerafast, Takara Bio Inc., and Kosheeka.

Established primary hepatocyte vendors operating in this sector have established long-term partnerships with scientists working on bioengineered liver regeneration and therapeutic cures. Meanwhile, the business of new players has been stimulated by the growing investigation of bioengineering applications for liver cell-based assays.

Recent Developments by Primary Hepatocyte Industry Participants

The United States-based BioIVT Company reported in May 2022 that high-purity Kupffer cells are now part of their newly released line of human primary hepatic cells. The firm further claims that these new cells are intended to aid in the development of different types of drugs and medications for liver disease.

In January 2022, Charles River Laboratories, based in the United States, purchased HemaCare Corp., one of the top suppliers of primary hepatocytes for use in research and clinical settings. Charles River has plans to increase its scientific capacity in the field of high-growth cell therapy after this purchase.

Key Segments Covered by Primary Hepatocytes Industry Survey Report

• By Product Type:

  • Cryopreserved Suspension Hepatocytes
  • Fresh Suspension Hepatocytes
  • 3D (Spheroid) Hepatocytes
  • Expanded Hepatocytes (Plateable)
  • Non-characterized Hepatocytes

• By Species Type:

  • Humans
  • Rats
  • Mice
  • Dogs
  • Monkeys
  • Horses
  • Other Species

• By Application or Assay:

  • Cell Viability Assays
  • Cytochrome Enzyme Activity
  • High Content Cytotoxicity
  • Transporter Inhibition Assays
  • In Vitro Intrinsic Clearance
  • Phospholipoid Assays
  • Other Applications or Assays

• By End User Verticals:

  • Biopharmaceutical Companies
  • Academic and Research Institutes
  • Contract Research Organizations
  • Other End User Verticals

• By Region:

  • North America
  • Europe
  • Latin America
  • East Asia
  • South Asia & Oceania
  • The Middle East & Africa (MEA)